In breast cancer cells, IL-4 exerts a wide spectrum of pro-tumorigenic effects by reducing expression of dual specificity phosphatase 4 (DUSP4), which negatively regulates ERK and p38 activity [46]. This evidence concerns the gene DUSP4 and breast cancer.